EGFR and colorectal carcinoma: Though RAS/RAF-dependent cancer cells are refractory to SHP2i monotherapy 147, SHP2i blocks EGFR-mediated MAPK rebound and confers sensitivity in BRAFi resistant CRC cells 138, 148, and synergizes with MEKi to suppress PDAC and NSCLC growth 149, 150.